Skip to main content

Table 1 Induction immunosuppressive drugs

From: New immunosuppressive drugs in heart transplantation

Agent Molecular target Molecular effect Specific side effects Comments
ATG/ALG Binds multiple antigens on lymphoid cells Complement-mediated lysis Serum sickness Batch variability
   Opsonization and clearance Thrombocytopenia  
   Modification of cell surface receptor Granulocytopenia  
OKT3 Binds T cell CD3 Complement mediated lysis Cytokine release syndrome Tachyphylaxis due to anti-idiotypic antibodies
   Opsonization and clearance (eg fever, chills, headache, and pulmonary edema)  
   Modification of CD3 receptor   
Daclizumab Binds α-subunit of interleukin-2 receptor Down-regulation of receptor No major side effects reported so far Humanized antibody
   ? CD4 T cell depletion   Long half-life (20 days)
     Five-dose regimen
Basiliximab Binds α-subunit of interleukin-2 receptor Down-regulation of receptor No major side effects reported so far Chimeric antibody
   ? CD4 T cell depletion   Long half-life (10-14 days)
     Two-dose regimen
  1. ALG, antilymphocyte globulin; ATG, antithymocyte globulin.
\